HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jones, P. W. Search for Related Content PubMed PubMed Citation Articles by Jones, P. W.

Clinical Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

St. George's Hospital Medical School, London, United Kingdom

Correspondence and requests for reprints should be addressed to Paul W. Jones, M.B.B.S., Ph.D., F.R.C.P., Professor of Respiratory Medicine, St. George's Hospital Medical School, London SW 17 0RE, UK. E-mail pjones{at}sghms.ac.uk

Chronic obstructive pulmonary disease (COPD) has multiple pathophysiologic effects that are not confined to the lungs. Similarly, treatment for COPD may have a number of different beneficial effects, and although each of these may be small, their cumulative effect may add up to a worthwhile overall outcome. Many of the effects of COPD are only weakly related to FEV₁, and there is good evidence that health status questionnaires are the best overall measures of disease severity. Recently it has been shown, using such instruments, that health status in patients with COPD deteriorates progressively and at a measurable rate. Fluticasone reduces that decline, an effect that may take months to be detectable but continues to develop over 3 years. The effect of fluticasone on health appears to be due to a reduction in exacerbations coupled with its small effect on FEV₁.

Key Words: dyspnea • exacerbations • health status